Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases. The company employs a structure based drug discovery platform and draws on Nobel Prize winning expertise to design small molecule medicines that are safe effective and convenient to administer. Its pipeline includes oral and inhaled candidates for influenza, a broad spectrum antiviral for norovirus and…
Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases. The company employs a structure based drug discovery platform and draws on Nobel Prize winning expertise to design small molecule medicines that are safe effective and convenient to administer. Its pipeline includes oral and inhaled candidates for influenza, a broad spectrum antiviral for norovirus and coronavirus infections and an investigational agent targeting the hepatitis C virus NS5B polymerase.
Cocrystal Pharma generates revenue primarily through collaboration and licensing agreements, such as its partnership with Merck Sharp & Dohme Corp for influenza A/B antiviral development. The company also receives proceeds from equity financings and may earn royalties or milestone payments from future partnered products. At present it does not have any approved commercial products that generate product sales revenue.
Cocrystal Pharma occupies a niche in the antiviral therapeutics market by focusing on conserved viral targets that are less prone to resistance. Its competitors include large pharmaceutical companies such as Roche Gilead Merck and Pfizer which market established influenza antivirals like Tamiflu Xofluza and Baloxavir as well as emerging biotechs such as Vaxart Moderna and Takeda that are developing norovirus and coronavirus vaccines or therapeutics. The company differentiates itself through its proprietary structure based platform which enables rapid identification of high affinity inhibitors and through its expertise in targeting highly conserved viral enzymes such as the PB2 polymerase of influenza and the 3CL protease of norovirus and coronavirus. This approach aims to deliver broad spectrum activity across strains and reduce the likelihood of drug resistance.
The company’s intended customers are patients suffering from influenza norovirus coronavirus and hepatitis C infections as well as the healthcare providers and public health agencies that treat these populations. In the near term its collaborators and licensing partners such as Merck represent key customers for its research and development assets. Successful commercialization would eventually shift the primary customer base to hospitals clinics pharmacies and individual patients seeking antiviral therapy.